To analyze national trends using the National Cancer Database (NCDB) in use of ADT, outside of standard of care, in patients with very low risk prostate cancer.
We identified 52,797 men in the NCDB from 2010 to 2015 diagnosed with very low risk prostate cancer as defined (cT1cM0, PSA<10, Gleason ≤ 6, < 3 biopsy cores positive).